JP2021536505A5 - - Google Patents

Info

Publication number
JP2021536505A5
JP2021536505A5 JP2021536673A JP2021536673A JP2021536505A5 JP 2021536505 A5 JP2021536505 A5 JP 2021536505A5 JP 2021536673 A JP2021536673 A JP 2021536673A JP 2021536673 A JP2021536673 A JP 2021536673A JP 2021536505 A5 JP2021536505 A5 JP 2021536505A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
compound according
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021536673A
Other languages
English (en)
Japanese (ja)
Other versions
JP7460264B2 (ja
JP2021536505A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/049374 external-priority patent/WO2020051153A1/en
Publication of JP2021536505A publication Critical patent/JP2021536505A/ja
Publication of JP2021536505A5 publication Critical patent/JP2021536505A5/ja
Application granted granted Critical
Publication of JP7460264B2 publication Critical patent/JP7460264B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021536673A 2018-09-04 2019-09-03 ムスカリン性アセチルコリンm1受容体アンタゴニスト Active JP7460264B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862726915P 2018-09-04 2018-09-04
US62/726,915 2018-09-04
PCT/US2019/049374 WO2020051153A1 (en) 2018-09-04 2019-09-03 Muscarinic acetylcholine m1 receptor antagonists

Publications (3)

Publication Number Publication Date
JP2021536505A JP2021536505A (ja) 2021-12-27
JP2021536505A5 true JP2021536505A5 (cg-RX-API-DMAC7.html) 2022-09-01
JP7460264B2 JP7460264B2 (ja) 2024-04-02

Family

ID=69721873

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021536673A Active JP7460264B2 (ja) 2018-09-04 2019-09-03 ムスカリン性アセチルコリンm1受容体アンタゴニスト

Country Status (7)

Country Link
US (2) US12054487B2 (cg-RX-API-DMAC7.html)
EP (1) EP3846806A4 (cg-RX-API-DMAC7.html)
JP (1) JP7460264B2 (cg-RX-API-DMAC7.html)
CN (2) CN119112895A (cg-RX-API-DMAC7.html)
AU (1) AU2019336671B2 (cg-RX-API-DMAC7.html)
CA (1) CA3108076A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020051153A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019241131A1 (en) 2018-06-11 2019-12-19 Pipeline Therapeutics, Inc. Muscarinic acetylcholine m1 receptor antagonists
CN119112895A (zh) 2018-09-04 2024-12-13 康蒂内乌姆医疗公司 毒蕈碱性乙酰胆碱m1受体拮抗剂
IL326597A (en) * 2019-10-07 2026-04-01 Contineum Therapeutics Inc Muscarinic acetylcholine m1 receptor antagonists
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
US20240217981A1 (en) * 2021-04-13 2024-07-04 Pipeline Therapeutics, Inc. Crystalline compound of muscarinic acetylcholine m1 receptor antagonists
CN117279917A (zh) * 2021-05-21 2023-12-22 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用
EP4359401A1 (en) * 2021-06-23 2024-05-01 Blueprint Medicines Corporation Process for preparing egfr inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803203A (en) 1986-11-05 1989-02-07 Warner-Lambert Company Phenyl and heterocyclic piperazinyl alkoxy-benzheterocyclic compounds as antipsychotic agents
US4873331A (en) 1988-12-09 1989-10-10 American Home Products Corporation Noradamantyl-carboxylic acid piperazinoalkyl esters
US5089497A (en) 1990-09-20 1992-02-18 Warner-Lambert Company Substituted piperazines as central nervous system agents
JP3204456B2 (ja) * 1995-12-21 2001-09-04 ファイザー・インコーポレーテッド 2,7―置換オクタヒドロ―ピロロ[1,2―a]ピラジン誘導体
AU2003212882A1 (en) 2002-02-01 2003-09-02 Euro-Celtique S.A. 2 - piperazine - pyridines useful for treating pain
WO2004073639A2 (en) 2003-02-19 2004-09-02 Merck & Co. Inc. Treatment of psychosis with a muscarinic m1 receptor ectopic activator
ES2325836T3 (es) 2004-07-26 2009-09-21 Merck Serono Sa Derivados de la n.hidroxiamida y uso de los mismos.
JP2009520689A (ja) 2005-12-01 2009-05-28 シェーリング コーポレイション 炎症障害および微生物性疾患を処置するための化合物
US20090156465A1 (en) 2005-12-30 2009-06-18 Sattigeri Jitendra A Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
WO2012020567A1 (en) 2010-08-09 2012-02-16 Raqualia Pharma Inc. Acyl piperazine derivatives as ttx-s blockers
UY34349A (es) * 2011-09-29 2013-04-05 Abb Vie Inc OCTAHIDROPIRROLO[1,2-a]PIRAZINA SULFONAMIDAS SUSTITUIDAS COMO BLOQUEADORES DE CANALES DE CALCIO
US9586964B2 (en) 2011-10-28 2017-03-07 Vanderbilt University Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1
US8697888B2 (en) 2012-01-06 2014-04-15 Vanderbilt University Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors
US20130289019A1 (en) 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
EP2897948B1 (en) 2012-09-18 2016-08-31 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists
JP6917989B2 (ja) 2015-11-06 2021-08-11 ニューロクライン バイオサイエンシーズ,インコーポレイテッド 神経学的疾患を処置するためのムスカリン受容体4(m4)アンタゴニストとしての、n−[2−(1−ベンジルピペリジン−4−イル)エチル]−4−(ピラジン−2−イル)−ピペラジン−1−カルボキサミド誘導体および関連化合物
EP3534901B1 (en) * 2016-11-07 2022-06-22 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2018089433A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
EP3752499B1 (en) 2018-02-15 2024-03-27 Boehringer Ingelheim International GmbH Inhibitors of trpc6
BR112020022006A2 (pt) 2018-04-30 2021-01-26 Ribon Therapeutics Inc. piridazinonas como inibidores de parp7
WO2019241131A1 (en) 2018-06-11 2019-12-19 Pipeline Therapeutics, Inc. Muscarinic acetylcholine m1 receptor antagonists
CN119112895A (zh) 2018-09-04 2024-12-13 康蒂内乌姆医疗公司 毒蕈碱性乙酰胆碱m1受体拮抗剂
IL326597A (en) 2019-10-07 2026-04-01 Contineum Therapeutics Inc Muscarinic acetylcholine m1 receptor antagonists
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists

Similar Documents

Publication Publication Date Title
US11702422B2 (en) Imidazopyridazines as modulators of IL-17
JP7555327B2 (ja) Nlrp3インフラマソーム阻害剤
JP6505013B2 (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
TWI662023B (zh) 治療活性化合物及其使用方法(二)
US7550481B2 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease
JP5693814B2 (ja) 新規のヒスタミンh3−受容体リガンドおよびそれらの治療的応用
JP6321825B2 (ja) 神経形成を刺激することができるn−フェニル−ラクタム誘導体及び神経障害の処置におけるそれらの使用
JP2019034943A (ja) Hbv感染に対する新規抗ウイルス剤
RU2712831C2 (ru) 3-оксо-3-(ариламино)пропионаты, способ их получения и их применение в получении пирролидинонов
TW201331177A (zh) 治療活性組合物及其使用方法
JP2011512359A (ja) プロスタグランジンd2受容体のアンタゴニストとしての環式ジアリールエーテル化合物
JP7008065B2 (ja) 腱及び/又は靭帯損傷に使用するためのアザ-インダゾール化合物
KR20190004742A (ko) 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
KR20230035049A (ko) 화합물, 조성물 및 방법
JP2021528405A (ja) RORγtのモジュレータとしてのアミド置換チアゾール
JP2021527660A (ja) RORγtのモジュレータとしてのフェニル及びピリジニル置換イミダゾール
JP2020518571A5 (cg-RX-API-DMAC7.html)
JP7158464B2 (ja) カリウムチャネル阻害剤としての置換ベンゾイミダゾール
JP2013541569A (ja) ジヒドロオキサゾール−2−アミン誘導体
JP2021512910A5 (cg-RX-API-DMAC7.html)
CN101602730B (zh) 取代的咪唑衍生物
JP2014001142A (ja) シクロアルカン化合物
WO2017008681A1 (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
TW202539691A (zh) SPPL2a抑制劑
JP2022151801A (ja) 複素環化合物